Nature Translational Psychiatry: patient-derived brain organoids show distinct functional neuronal signatures in psychiatric disorders
Summary
A Nature Translational Psychiatry study using Israeli neurotech company Itay&Beyond's platform demonstrated distinct functional neuronal signatures in patient-derived brain organoids from individuals with treatment-resistant depression, bipolar disorder, and schizophrenia — versus healthy controls. The functional signatures matched clinical treatment response patterns, suggesting organoid-based neural activity profiles could serve as predictive biomarkers for psychiatric drug selection. GlobeNewswire covered the Itay&Beyond platform as enabling this research.
Why it matters
Patient-derived organoids with distinct psychiatric disorder functional signatures that predict treatment response is the holy grail for precision psychiatry — enabling biological subtyping of what are currently symptom-defined diagnostic categories. If organoid neural activity profiles can predict which drug will work for a specific patient, psychiatric treatment selection could become as precise as pharmacogenomic-guided oncology.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial